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Abstract   
 
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are 
required to alleviate the associated morbidity and mortality.  Investigating the anti-fibrotic 
efficacy of drugs that are already in clinical practice offers an efficient strategy to identify new 
therapies.  The phosphodiesterase 4 (PDE4) inhibitors, approved for the treatment of chronic 
obstructive pulmonary disease, harbor therapeutic potential for pulmonary fibrosis by 
augmenting the activity of endogenous anti-fibrotic mediators that signal through cyclic AMP.  In 
the present study, we tested the efficacy of several PDE4 inhibitors including a novel compound 
(Compound 1) in a murine model of lung fibrosis that results from a targeted type II alveolar 
epithelial cell injury.  We also compared the anti-fibrotic activity of PDE4 inhibition to the two 
therapies that are FDA-approved for idiopathic pulmonary fibrosis (pirfenidone and nintedanib).  
We found that both preventative (day 0-21) and therapeutic (day 11-21) dosing regimens of the 
PDE4 inhibitors significantly ameliorated the weight loss and lung collagen accumulation that 
are the sequelae of targeted epithelial cell damage.  In a therapeutic protocol, the reduction in 
lung fibrosis with PDE4 inhibitor administration was equivalent to pirfenidone and nintedanib.   
Treatment with this class of drugs also resulted in a decrease in plasma surfactant protein D 
concentration, a reduction in the plasma levels of several chemokines implicated in lung fibrosis, 
and an in vitro inhibition of fibroblast pro-fibrotic gene expression.  These results motivate 
further investigation of PDE4 inhibition as a treatment for patients with fibrotic lung disease.    
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Introduction: 
Fibrosis of the lung interstitium occurs in response to multiple insults.  Inhalation of 
organic and inorganic dusts and systemic exposure to specific medications including 
chemotherapy can all induce alveolar scarring.  Lung fibrosis is also associated with a subset of 
rheumatologic diseases including systemic sclerosis and rheumatoid arthritis.  In idiopathic 
pulmonary fibrosis (IPF), interstitial scarring occurs in the absence of an identifiable injury, 
although type II alveolar epithelial cell specific gene mutations are found in a subset of patients 
with both sporadic and familial forms of this disease (1, 2).  All of these disorders that result in 
fibrosis of the lung interstitium are associated with significant morbidity and mortality.  However, 
IPF arguably represents the greatest therapeutic challenge as this disease portends a median 
survival of only 3 years, and less than 20% of patients with this disease live beyond eight years 
of their initial diagnosis (2).  The recent FDA approval of two new therapies for the treatment of 
IPF (pirfenidone and nintedanib) has resulted in guarded optimism, but there continues to be a 
desperate need for additional anti-fibrotic medications with increased efficacy and fewer side 
effects (3, 4).  
One approach to identify novel anti-fibrotic therapies is to investigate the efficacy of 
currently FDA approved agents that target specific pro-fibrotic mechanisms.  A significant 
advantage of this approach to repurpose existing compounds is the potential for rapid 
translation into patients because of the existing pharmacokinetic and pharmacodynamic data 
and safety studies in humans.  As an example, phosphodiesterase 4 (PDE4) inhibitors including 
roflumilast, which is approved for the treatment of chronic obstructive pulmonary disease 
(COPD), hold promise as anti-fibrotic agents.  This class of drugs blocks the degradation of 
cAMP and thereby augments the activity of anti-fibrotic mediators that signal through G protein-
coupled receptors including prostaglandin E2 (PGE2), prostacyclin, and adenosine.  PGE2 
5-8
exhibits a multitude of anti-fibrotic effects including inhibiting fibroblast activation, increasing 
fibroblast susceptibility to apoptosis, and maintaining alveolar epithelial cell integrity ( ).  The 
anti-fibrotic potential of PDE4 inhibitors is supported by several in vitro studies.  Specifically, the 
PDE4 inhibitor piclamilast was found to blunt transforming growth factor-beta (TGF-β)-mediated 
fibroblast to myofibroblast differentiation, an effect that was accentuated by the addition of 
exogenous PGE2  9( ).  In a separate in vitro study, roflumilast inhibited both TGF-β stimulated 
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fibroblast contraction of 3-dimentional collagen gels and fibroblast chemotaxis toward fibronectin 
(10).  Importantly, roflumilast also increased PGE2 
11
release by fibroblasts.  PDE4 inhibitors have 
also been found to mitigate bleomycin induced fibrosis in vivo.  Specifically, the initiation of 
roflumilast treatment on day 0 and day 7 following bleomycin injury reduced day 14 and day 21 
lung fibrosis respectively ( ) .  In a separate study, roflumilast also reversed the metabolic 
alterations of bleomycin injury when administered in a preventative regimen (12).    
The aforementioned studies supporting the anti-fibrotic potential of PDE4 inhibitors led 
us to further investigate the efficacy of this class of medications in a murine model of lung 
fibrosis that results from a targeted insult to the type II alveolar epithelium (13).  We 
hypothesized that both preventative and therapeutic PDE4 inhibitor administration protocols 
would mitigate pulmonary fibrosis in this model.  Type II alveolar epithelial cell injury-induced 
fibrosis differs from bleomycin in that the inflammatory response is modest (marked by the 
selective accumulation of Ly-6c high monocytes and exudate macrophages) and the resultant 
fibrosis is more diffuse (13-15) .  PDE4 inhibitors including piclamilast, roflumilast and a novel 
agent (Compound 1) were tested and the efficacy of PDE4 inhibition was compared to 
pirfenidone and nintedanib.  The effect of PDE4 inhibition on lung chemokine levels, whole lung 
fibrogenic gene expression, and plasma surfactant protein D (SP-D) levels (as an indicator of 
epithelial cell integrity) was also measured (1).   
We found that both prophylactic and therapeutic administration of PDE4 inhibitors 
including the novel agent Compound 1 significantly reduced lung fibrosis following type II AEC 
injury with an efficacy comparable to pirfenidone and nintedanib.  The protection against lung 
fibrosis was associated with diminished weight loss and a significant decline in plasma SP-D 
levels.  These findings highlight the antifibrotic potential of PDE4 inhibition, and with roflumilast 
already FDA approved for the treatment of COPD and additional novel agents on the horizon, 
our data motivate the clinical investigation of this class of drugs in patients with IPF and other 
fibrotic lung diseases. 
 
Methods: 
Animals:  All animal experiments were performed in accordance with institutional guidelines set 
forth by the University Committee on the Use and Care of Animals at the University of Michigan.  
Transgenic mice expressing the diphtheria toxin receptor (DTR) under the control of the murine 
SPC promoter were generated in our laboratory on a C57BL/6 background (designated DTR+ 
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mice) (13).  The presence of the DTR was detected using PCR for the SPC-DTR transgenic 
construct as previously described (13).  Control mice included littermates of SPC-DTR 
transgenic mice that were PCR-negative for the transgenic construct and C57BL/6 mice 
purchased from Jackson Laboratories (Bar Harbor, ME).  These control animals are designated 
DTR- and prior studies revealed that neither of these strains of mice develop significant fibrosis 
in response to diphtheria toxin (DT) administration.  
 
Drug concentration and cAMP levels:
where Cn and AUCn represent the plasma concentration and the AUC of active 
pharmacological ingredient (API) respectively, fu is the unbound fraction in plasma, IC50 is the 
concentration resulting in 50% inhibition in an in vitro assay and n represents the number of 
APIs(
 Roflumilast (5 mg/kg) and Compound 1 (10 mg/kg) were 
administered to C57BL/6N mice (Charles River Laboratories Japan, Inc., Japan) which were 
then sacrificed at 0.5, 1, 2, 4, 8 and 24 hours after the dosing. Blood samples were collected 
and centrifuged to obtain plasma specimens. Plasma concentrations of roflumilast, the active 
metabolite of roflumilast N-oxide and Compound 1 were measured using liquid 
chromatography/tandem mass spectrometry. Bronchoalveolar Lavage Fluid (BALF) was 
collected by instilling 3 aliquots of 0.5 mL 0.9% saline into the lungs. BALF was centrifuged to 
remove cells, the supernatant was deproteinized with trichloroacetic acid, and washed by 
diethylether. The aqueous layer was freeze-dried and dissolved by lysis buffer enclosed in 
cAMP XP Assay kit (Cell Signaling Technology Inc., MA, USA). cAMP content was measured in 
accordance with the manufacturer's instruction, and, total PDE4 inhibitory activities (tPDE4i) 
were calculated by following equation: 
tPDE4i =  � (�� �� ����) × �����50�  
18). Of note, roflumilast has two APIs and Compound 1 has one API. 
 
Preparation of test compounds
16
:  All drugs were suspended in 0.5% methylcellulose and 
administered by oral gavage.  Roflumilast (1.0 and 5.0 mg/kg), piclamilast (30 mg/kg) and 
Compound 1 (N-[Amino(dimethylamino)methylidene]-4-[(3aS,9bR)-8-ethoxy-7-methoxy-
1,3,3a,9b-tetrahydrofuro[3,4-c]isoquinolin-5-yl]benzamide at 1.0, 5.0, and 10.0 mg/kg) were 
given once daily by gavage.  Pirfenidone was dosed at 100 mg/kg three times daily ( ) and 
nintedanib was dosed at 100 mg/kg twice daily (17) by gavage. 
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Diphtheria Toxin Administration and Experimental Design:
 
  Six to ten week old mice were 
intraperitoneally injected with DT (Sigma Chemical, St. Louis, MO) once daily for 14 days at a 
dose of 12.5 µg/kg in 100 µl of PBS.  Control groups received intraperitoneal PBS alone.  
Prophylactic dosing of the experimental treatments was initiated on day 1 and continued daily at 
the indicated doses throughout the 21 day study protocol.  Therapeutic dosing was initiated on 
day 11 and continued daily at the indicated doses for 10 days.  Mice were weighed daily and, on 
day 21 of the study protocol (7 days after the last dose of DT), blood and lungs were harvested 
1 hour after the last drug administration.  Lungs were either sectioned for histology or 
homogenized for hydroxyproline analysis and whole lung gene expression.  Plasma was 
separated from whole blood and analyzed for chemokine and SP-D levels.  
Hydroxyproline assay
13
:  Hydroxyproline content of both lungs was measured as previously 
reported ( ). 
Lung histology:  The left lung was inflation-fixed at 25 cm H2O pressure with 10% neutral-
buffered formalin, removed en bloc, further fixed in 10% neutral-buffered formalin overnight, and 
then paraffin embedded.  Five micron sections were stained using picrosirius red. 
Plasma SP-D levels:
 
 Plasma SP-D levels were measured using SP-D ELISA Kit (Yamasa Corp., 
Japan).  Samples were diluted using the provided buffer and measurements were made in 
accordance with the manufacturer's protocol. 
Plasma Chemokine analysis:
 
 Plasma chemokine concentrations were measured using the 
Milliplex MAP mouse cytokine/chemokine magnetic bead panel kit (Merck Millipore Corp., 
Germany) according to the manufacturer’s instructions. 
In vitro fibroblast studies: For cAMP assay, WI-38 human lung fibroblasts were suspended in E-
MEM (Thermo Fisher Scientific Inc., MA,USA) containing 10% heat-inactivated fetal bovine 
serum (FBS) and seeded on 24-well plates at 50,000 cells/500 μL/well. Twenty-four hours after 
seeding, cells were treated with Compound 1 (1×10-10 M - 1×10-5 M) dissolved in HBSS 
(Thermo Fisher Scientific Inc., MA,USA) containing 0.1 % bovine serum albumin (BSA) and 5 
mM HEPES. After 30 min, cells were stimulated by 1 μM forskolin for 30 min and then lysed.  
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cAMP was measured in accordance with the cAMP XP Assay kit protocol (Cell Signaling 
Technology Inc., MA, USA). 
To analyze fibroblast gene expression, WI-38 human lung fibroblasts were suspended in E-
MEM (Thermo Fisher Scientific, MA, USA) containing 10% heat-inactivated FBS and seeded on 
24 well plates at 50,000 cells/500 μL/well. After seeding, cells were cultured in E-MEM 
containing 0.5% FBS for 24 hours. The cultures were then treated with Compound 1 (1×10-10 
M - 1×10-5 M) for 1 hour followed by TGF-β (3 ng/mL) and forskolin (1 μM) for 24 hours. Total 
RNA was extracted from cell lysate using RNeasy 96 Kit (QIAGEN, Germany). cDNA was 
amplified using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, MA, 
USA), and target gene mRNA was measured using TaqMan PCR (7900HT Thermo Fisher 
Scientific, MA, USA). The target gene expression level was normalized by mRNA expression of 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  TaqMan gene expression assays 
(Thermo Fisher Scientific, MA, USA) were used to measure gene expression.  Assay ID of 
human GAPDH, type-1 collagen, fibronectin, connective tissue growth factor and plasminogen 
activator inhibitor-1 were Hs02758991g1, Hs00164004m1, Hs00365052m1 Hs01026927g1 and 
Hs00167155m1, respectively. 
 
In vitro A549 cell studies: 
 
For cAMP assays, A549 human lung epithelial cells were suspended 
in Ham's F-12K (Thermo Fisher Scientific Inc., MA,USA) containing 10% heat-inactivated FBS 
and seeded on 24 well plates as 50,000 cells/500 μL/well for 24 hours. Cells were treated with 
Compound 1 (1×10-10 M - 1×10-5 M) dissolved in HBSS (Thermo Fisher Scientific Inc., 
MA,USA) containing 0.1% bovine serum albumin (BSA) and 5 mM HEPES for 30 minutes and 
stimulated with 10 μM forskolin and 10 μM prostaglandin E2 for 30 min. Cells were lysed and 
cAMP content in cell lysates and supernatants were measured using cAMP XP Assay kit (Cell 
signaling technology, MA, USA). 
Quantitative RT-PCR on lung homogenates:  RNA was isolated from the left lung using the 
RNeasy Plus Mini Kit (Qiagen) and first-strand cDNA was synthesized using SuperScriptIII 
(Invitrogen, Carlsbad, CA). Specific qPCRs with SYBR Green-based detection using an MX 
3000P system (Stratagene, La Jolla, CA) were conducted for forty cycles (94°C for 15 seconds 
followed by 60°C for 30 seconds and 72°C for 30 seconds) using each cDNA template. The 
mRNA levels were normalized with the expression of GAPDH using the following formula: 
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%GAPDH expression = 100/ 2-ΔΔCT.  Primer pairs for murine collagen1a1, tumor necrosis 
factor α, fibronectin, connective tissue growth factor, and plasminogen activator inhibitor 1 were 
purchased from Applied Biosystems.   
Statistical Analysis.
Results: 
  All data were expressed as mean ± SEM.  Data were evaluated by 
unpaired Student’s t-test (for comparison between two samples), a two-tailed William’s test, 
one-way ANOVA with a Tukey multiple comparisons test or a two-way ANOVA with a Tukey 
multiple comparisons test.  A statistically significant difference was accepted at p<0.05. 
Pharmacokinetics of the phosphodiesterase 4 inhibitors: 
 Prior to testing the efficacy of PDE4 inhibitors in our murine model of lung fibrosis, we 
assessed the pharmacokinetics of Compound 1 with our planned dosing regimen in uninjured 
wild-type mice.   Compound 1 is a novel PDE4 inhibitor with a different structural scaffold than 
Roflumilast and Piclamilast, and in contrast to Piclamilast and Roflumilast which both inhibit 
CYP3A4, Compound 1 has no CYP inhibitory activity.  For Compound 1, a single dose of (10.0 
mg/kg) was administered by oral gavage at time 0.  Plasma was then collected at 0.5, 1.0, 2.0, 
4.0, 8.0 and 24.0 hours.  Bronchoalveolar lavage fluid (BALF) was collected simultaneously and 
analyzed for cAMP levels.  As demonstrated in Figure 1A, the 10.0 mg/kg dose of Compound 1 
resulted in a peak plasma concentration at 0.5 hours of 1585.4 tPDE4i.  The plasma level then 
decreased over the next 8 hours to a level of 96.1, and this low PDE4i of drug persisted at 24 
hours.  The BALF concentration of cAMP correlated with the drug level of the PDE4 inhibitor 
with a peak level of 27.4 pmol/mg protein occurring at the 0.5 hour time point (up from a basal 
concentration of 7.9 pmol/mg protein) (Figure 1B).  By 8 hours, the BALF concentration of 
cAMP had returned to basal levels.  Figure 1C demonstrates the linear increase in the BALF 
concentration of cAMP in direct relation to the increasing drug level of Compound 1 suggesting 
that BALF cAMP concentration can be used as a marker of drug effect in the target tissue.  
Similar pharmokinetics were observed following a single administration of roflumilast at 
5.0 mg/kg (data not shown).  The peak concentration was measured at 0.5 hours and returned 
to baseline at 8 hours.  As was the case with Compound 1, the BALF concentration of cAMP 
correlated with the drug level of the PDE4 inhibitor with a peak level of 33.3 pmol/mg protein 
occurring at the 0.5 hour time point (up from a basal concentration of 10.9 pmol/mg protein) and 
returning near baseline by 8 hours (data not shown). 
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Prophylactic administration of piclamilast and roflumilast in the type II AEC injury model 
of lung fibrosis: 
 To determine if PDE4 inhibition would mitigate pulmonary fibrosis that results from 
targeted type II AEC injury, we treated DTR+ mice with daily doses of intraperitoneal DT for 14 
days.  In previous studies, we demonstrated that this dosing regimen induced a progressive 
weight loss and lung fibrosis that was readily detected by day 21, one week after the last DT 
injection (13).    To assess the efficacy of PDE4 inhibition in this model, we initially administered 
a prophylactic dosing regimen of piclamilast (30 mg/kg daily) or roflumilast (1.0 and 5.0 mg/kg) 
via oral gavage beginning on day 0 and continuing through day 21 of the model.  By treating 
throughout the 21 day experimental time course, we sought to optimize our ability to detect a 
significant effect of PDE4 inhibition in our fibrosis model.  We found that treatment of DTR+ 
mice with either piclamilast or roflumilast blunted the decline in body weight due to DT 
administration (Figure 2A).  By day 11, the protection against weight loss afforded by these two 
drugs was statistically significantly different when compared to the vehicle-treated DTR+-DT 
injured mice.  Treatment with either drug (and for roflumilast, both doses) resulted in a 
significant reduction in lung collagen content as measured by hydroxyproline compared to DT-
injured DTR+ mice that were treated with vehicle (Figure 2B).  The resulting level of lung 
hydroxyproline following PDE4 inhibition was similar to the uninjured control groups (i.e. DTR- 
mice treated with DT and DTR+ mice treated with PBS).         
   
Prophylactic administration of Compound 1 and piclamilast in the type II AEC injury 
model of lung fibrosis: 
 After confirming the efficacy of prophylactic PDE4 inhibition with piclamilast and 
roflumilast in reducing fibrosis following targeted type II AEC injury, we next assessed whether 
the novel PDE4 inhibitor Compound 1 would also protect against fibrosis in our murine model.  
Compound 1 was administered daily at doses of 1.0 mg/kg, 5.0 mg/kg and 10.0 mg/kg from day 
0 through day 21.  The efficacy of this molecule was compared to daily treatment with 
piclamilast (30 mg/kg).  We found that all doses of Compound 1 lessened the DT-injury induced 
weight loss in DTR+ mice, and the protection afforded by this agent (at each dose) was 
comparable to piclamilast (Figure 3A).  By day 15, the weight losses in the groups of DTR+-DT 
injured mice receiving the three doses of Compound 1 were significantly less than in the 
vehicle-treated DTR+-DT injured group.  All doses of Compound 1 also significantly reduced the 
day 21 lung collagen content when compared to DT-injured DTR+ mice that were treated with 
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vehicle (Figure 3B).  Also, the levels of lung hydroxyproline in the 3 dose groups of Compound 
1 were not statistically different from the group that was treated with 30 mg/kg of piclamilast. 
 
Therapeutic administration of Compound 1 and roflumilast in the type II AEC injury 
model of lung fibrosis: 
 We next tested whether PDE4 inhibition would also diminish lung fibrosis when delivered 
in a therapeutic protocol.  For these experiments, DTR+ mice were administered daily doses of 
DT from day 1 through day 14.   From day 11 through day 21, subsets of mice were treated with 
Compound 1 at doses of 1.0 mg/kg or 5.0 mg/kg, roflumilast at 5.0 mg/kg, or vehicle.  The time 
point of treatment initiation was chosen based on our prior studies which demonstrated that the 
onset of fibrosis was detectable around day 11 and that 10 days of treatment was sufficient to 
detect a therapeutic effect of a previously studied anti-fibrotic drug (19).  Weight loss was 
tracked throughout the study, and the severity of lung fibrosis was assessed on day 21 by lung 
hydroxyproline concentration and picrosirius red-stained histologic sections.  At the time of 
treatment initiation on day 11, the mean body weight was equivalent in all DT-treated DTR+ 
cohorts.  Treatment with the PDE4 inhibitors limited the further decline in body weight that was 
observed in the vehicle treated group from day 11 through day 21 (Figure 4A, p ≤ 0.05 on day 
21 for Compound 1 (5.0 mg/kg) and Roflumilast (5.0 mg/kg)-treated mice compared to the 
vehicle treated group).  In the 5.0 mg/kg doses of Compound 1 and roflumilast groups, the 
PDE4 inhibitor-mediated protection against weight loss was associated with a significant 
reduction in lung collagen content (Figure 4B).  Of note, the 1.0 mg/kg therapeutic treatment 
dose of Compound 1 did not significantly reduce lung collagen content compared to the group 
that received vehicle, suggesting that this dose is below the efficacy threshold.  The therapeutic 
administration of Compound 1 at 5.0 mg/kg also substantially reduced picrosirius red staining 
(specific for collagen) and alveolar wall thickening characteristic of the histologic abnormalities 
observed in DT-injured DTR+ mice on day 21 (Figure 4C).  
 
Compound 1 increases cAMP levels in A549 cells and reduces plasma surfactant protein 
D levels: 
 After establishing both prophylactic and therapeutic efficacy of PDE4 inhibition in 
mitigating type II AEC injury-induced lung fibrosis, we performed studies to gain insight into the 
mechanisms by which this class of drugs exerts its anti-fibrotic effect.  We first examined 
whether alveolar epithelial cells were responsive to PDE4 inhibition by measuring the level of 
cAMP following Compound 1 treatment.  For these studies, A549 cells, a malignant human 
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alveolar epithelial cell line, were treated with increasing doses of Compound 1 (in the presence 
of 10 µM PGE2 and 10 µM forskolin to stimulate cAMP production).  As demonstrated in Figure 
5A and Figure 5B, Compound 1 induced a dose dependent increase in cAMP concentrations in 
both cell lysates and conditioned media.  At lower concentrations of intracellular cAMP (below 
20 pmol/mg protein), a linear relationship existed between intracellular and extracellular levels 
of this mediator (Figure 5C).  After confirming activity in A549 cells, we examined whether 
Compound 1 (1.0 mg/kg, 5.0 mg/kg and 10.0 mg/kg) or piclamilast (30 mg/kg) modulated 
alveolar epithelial cell integrity following targeted type II AEC injury by measuring day 21 plasma 
surfactant protein D (SP-D) levels.  Using the prophylactic treatment protocol, we found that all 
three doses of Compound 1 and the 30 mg/kg dose of piclamilast significantly reduced plasma 
SP-D compared to DT-injured DTR+ mice treated with vehicle (Figure 6A).  Of note, there was 
a weak but statistically significant correlation between the plasma SP-D level at day 21 and lung 
collagen content in individual mice (r2
 
 = 18.7%, p=0.0053) (Figure 6B).  
Compound 1 treatment decreases the plasma level of select chemokines: 
 As another potential mechanism by which PDE4 inhibition reduces lung fibrosis in the 
setting of targeted type II AEC injury, we determined whether Compound 1 altered plasma 
levels of a select subset of chemokines.  For these studies DT-injected DTR mice were treated 
with a therapeutic administration of Compound 1 at 5.0 mg/kg.  Plasma was collected on day 
21, and levels of eotaxin (CCL11), IP-10 (CXCL10), LIX (CXCL5) and Rantes (CCL5) were 
measured by bead-based multi-analyte profiling.  We found that PDE4 inhibition with Compound 
1 reduced the concentration of all of these mediators with the greatest effect on CXCL5 and 
CCL5 (Figure 7).  
 
Compound 1 treatment decreases fibrogenic gene expression in fibroblasts in vitro and 
blunts TNFα expression in vivo: 
 Fibroblasts and myofibroblasts are considered the primary effector cells in tissue 
fibrosis.  These cells are the primary source of key extracellular matrix constituents including the 
fibrillar collagens (including collagen 1) and fibronectin (Fn).  These cells also secrete other 
profibrotic molecules including plasminogen activator inhibitor 1 (PAI-1) and connective tissue 
growth factor (CTGF).  Prior studies have demonstrated that PDE4 inhibitors impede certain 
fibroblast functions including 3-dimentional gel contraction, migration, and myofibroblast 
differentiation (9-10).  To assess whether PDE4 inhibition also influenced fibroblast expression 
of pro-fibrotic mediators, WI-38 human lung fibroblasts were treated with increasing doses of 
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Compound 1 in the presence of forskolin (1.0 µM) and transforming growth factor-β (TGF-β, 3.0 
ng/ml).  We then measured the expression levels of Fn, collagen 1α1, PAI-1, and CTGF.  
Exposure of WI-38 cells to Compound 1 in the presence of forskolin increased the level of 
intracellular cAMP in a dose dependent manner (Figure 8).  This increase in intracellular cAMP 
reduced the TGF-β stimulated expression of Fn, collagen 1α1 chain, PAI-1, and CTGF in a 
dose-dependent manner (Figure 8).   
To determine if treatment with Compound 1 also inhibited profibrotic gene expression in 
vivo, DT-injured DTR+ mice were treated with 5.0 mg/kg of Compound 1 from day 11 through 
day 21.  On day 21, RNA was purified from lung tissue, and message levels for murine TNFα, 
collagen 1α1, PAI-1, CTGF and Fn were assessed by quantitative RT-PCR.  We found that only 
TNFα expression was significantly reduced at the day 21 time point (Figure 9B).  The mean 
expression of collagen 1α1, CTGF and Fn were also decreased, but the reduction did not 
achieve statistical significance from the vehicle treated DT-injured DTR+ group (Figure 9A, C, 
D). 
 
The therapeutic efficacy of PDE4 inhibition versus pirfenidone and nintedanib:   
 After establishing a therapeutic benefit of roflumilast and Compound 1 in reducing type II 
AEC injury-induced fibrosis, we next compared the efficacy of PDE4 inhibition to treatment with 
the two FDA approved drugs for IPF (pirfenidone and nintedanib).  DT was administered for 14 
days according to our standard protocol.  Beginning on day 11, subsets of DT-injured DTR+ 
mice were treated with vehicle, roflumilast (5 mg/kg once daily), pirfenidone (100 mg/kg 3 times 
daily), or nindetinib (100 mg/kg twice daily).  For pirfenidone and nintedanib, doses were chosen 
based on PK profiles and published data in the bleomycin model.  The mice were weighed daily, 
and on day 21, lungs were harvested for lung collagen content.  Consistent with our prior 
results, we found that roflumilast blunted the weight loss induced by DT administration in the 
DTR+ animals.  Pirfenidone also reduced weight loss compared to the vehicle treated group.  In 
contrast, therapeutic administration of nintedanib accentuated weight loss in this fibrosis model 
(Figure 10A, p ≤ 0.05 on day 20-21 for roflumilast and pirfenidone-treated mice compared to 
the nintedanib-treated group).  Measurements of lung hydroxyproline revealed that all three 
drugs effectively reduced type II AEC-injury induced fibrosis, and there was no difference in the 
anti-fibrotic efficacy of these agents at the given doses (Figure 10B). 
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Discussion: 
 Diseases that are characterized by tissue fibrosis constitute major clinical challenges.  
Therefore, the approval of the first two drugs for patients with IPF, the prototypic scarring 
disorder of the lung, created excitement in the pulmonary community (20, 21).  Despite this 
recent advance, there is still a desperate need for additional well-tolerated and efficacious 
treatments, and exploring the anti-fibrotic effect of already approved drugs with acceptable 
safety profiles offers an efficient approach to meet this demand.  In this regard, we investigated 
the antifibrotic activity of both prophylactic and therapeutic PDE4 inhibitor administration in a 
type II AEC injury model of lung fibrosis.  We found that 3 different members of this drug class 
including roflumilast (which is FDA approved for the treatment of COPD) and the novel agent 
The efficacy of Compound 1 in reducing lung fibrosis and blunting the associated weight loss  
was similar to roflumilast and piclamilast.  Although roflumilast is known to show a body weight 
lowering effect in the clinical setting, treatment with the tested PDE4 inhibitors has a beneficial 
effect on weight loss in our fibrosis model compared to nintedanib and, less so, pirfenidone.  
Importantly, the antifibrotic activity of PDE4 inhibition in this model was equivalent to these two 
FDA-approved therapies for IPF. 
 A large number of potential antifibrotic therapies have been shown to reduce fibrosis 
following bleomycin-induced lung injury (22).  Based on their promising effect in this rodent 
model, a subset of these agents has been tested in well-designed clinical trials with frustrating 
results.  This lack of translation has led the fibrosis research community to question the utility of 
the bleomycin model in predicting the efficacy of prospective drugs.  It should be noted, 
however, that the anti-fibrotic benefit of the majority of these drugs in the bleomycin model was 
established with preventative/prophylactic dosing.  Because bleomycin induces inflammation 
which is a key element of the lung injury in this model, prophylactic administration of any drug 
that alters this inflammatory response is likely to impact fibrosis even if the agent lacks specific 
anti-fibrotic activity. 
In light of this limitation of bleomycin, we chose to employ our type II AEC targeted injury 
model of lung fibrosis to evaluate the efficacy of the PDE4 inhibitors.  This model shares 
pathogenic features with the human disease.  For example, histologic studies consistently 
demonstrate type II cell defects including hyperplasia and apoptosis in patients with IPF (23-25).  
Also, AEC-specific gene mutations including surfactant proteins A2 and C are linked to familial 
lung fibrosis (26, 27) .  The limited and specific inflammatory response that occurs in this model 
may also better mimic the human disease (15) .  To further enhance the translatability of our 
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findings, we tested the efficacy of the PDE4 inhibitors not only in a preventative treatment 
regimen but also with therapeutic dosing (i.e. day 11-21).  Although the potent effect of the 
PDE4 inhibitors in mitigating type II AEC injury-induced fibrosis should motivate the further 
development of this class of drugs for patients with IPF, we acknowledge that the predictive 
value of our model of fibrosis requires validation.  It should also be mentioned that the two 
approved therapies for IPF (nintedanib and pirfenidone) comprise a small group of drugs that, 
when administered therapeutically, reduced bleomycin-induced fibrosis, suggesting that results 
from the bleomycin model, in the right context, can also guide clinical research decisions (28, 
29).  Furthermore, nintedanib and pirfenidone significantly reduce fibrosis in both the bleomycin 
and type II AEC injury models, supporting the notion that efficacy in several distinct models of 
fibrosis helps predict translatability to human disease. 
Multiple anti-fibrotic mediators including PGE2, prostacyclin, and adenosine signal 
through cAMP, motivating our interest in evaluating the efficacy of PDE4 inhibitors in our animal 
model of fibrosis.  Amongst the pleiotropic anti-fibrotic effects of PGE2, it has been shown to 
protect the lung epithelium.  For example, prior studies reveal that PGE2 
8
inhibits Fas ligand 
induced apoptosis of type II AECs isolated from fibrotic lungs ( ) .  This lipid mediator also 
promotes in vitro wound repair of airway epithelial cells (30).  In our studies, treatment with 
Compound 1 effectively increased cAMP levels in an alveolar epithelial cell line, and we 
observed that the in vivo administration of this drug significantly reduced the plasma levels of 
SP-D following targeted type II AEC injury in mice.  Of note, SP-D is increased in the serum of 
patients with IPF, and several studies indicate that this molecule, either alone or in conjunction 
with other proteins, functions as a diagnostic and prognostic biomarker in IPF (31-33).  Although 
the mechanism by which serum levels of SP-D are increased in IPF and other lung fibrotic 
disorders is unknown, ongoing type II AEC injury in conjunction with hyperplasia likely 
contributes (34, 35).  The PDE4 inhibitor-mediated decrease in the plasma concentration of SP-
D after the cessation of DT supports an effect of this class of drugs on the alveolar epithelium as 
an element of their anti-fibrotic activity. 
In addition to promoting the integrity of the alveolar epithelium, PGE2 as well as 
prostacyclin analogs  have been found to hinder a myriad of fibroblast functions.  Specifically, 
PGE2
36
 and treprostinil inhibit TGF-β-induced myofibroblast differentiation and promote the 
reversal of differentiated myofibroblasts to fibroblasts ( , 37, 38).   In addition, PGE2
7
 impedes 
the proliferation and migration of fibroblasts and also increases their susceptibility to apoptosis 
( , 8).  In the setting of lung fibrosis, these anti-fibrotic activities of PGE2
39
 are mitigated by a 
down-regulation of its receptor in addition to an inhibition of its synthesis ( , 40).  Through the 
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preservation of intracellular cAMP levels, PDE4 inhibitors have the capacity to augment the 
residual inhibitory actions of PGE2
10
 on fibroblasts, and indeed, prior studies have found that 
roflumilast slows migration and reduces 3-dimentional gel contraction by these cells ( ).  In the 
current study, we extend these findings by demonstrating that Compound 1-mediated PDE4 
inhibition decreases in vitro fibroblast expression of several profibrotic mediators including Col 
1a1, Fn and PAI-1.  Of note, we did not find a significant PDE4 inhibitor-induced reduction in the 
expression of these same genes in vivo although we did observe a trend for decreased 
expression of Col 1a1, Fn.  This lack of a statistically significant effect on pro-fibrotic gene 
expression may be a reflection of the chosen time point for these studies, as we have previously 
shown that lung collagen content does not appreciably increase beyond day 21 in the type II 
AEC injury model(13).  Our findings might also be attributed to the dilution of a PDE4 inhibitor 
mediated effect in a specific cell population (i.e. fibroblast) resulting from the assessment of the 
whole lung RNA.  We more likely would have detected a significant effect of PDE4 inhibition on 
profibrotic gene expression if measured specifically in fibroblasts on day 14 when collagen 
production is ongoing. 
Beyond its effect of the alveolar epithelium and fibroblasts, it is also plausible that PDE4 
inhibition limited fibrosis following type II AEC injury through an anti-inflammatory effect.  
Notably, our prior studies have implicated a specific monocyte/macrophage predominant 
inflammation in the development of type II AEC-injury induced fibrosis.  In the current study, we 
found that Compound 1 treatment significantly reduced the plasma levels of a subset of 
chemokines that are upregulated in pulmonary fibrosis and/or are influenced by cAMP signaling.  
Specifically, CXCL5/LIX concentrations were found to be increased in the lavage fluid of 
systemic sclerosis patients with associated interstitial lung disease (41), and elevated levels of 
CCL5/RANTES were measured in the BALF of IPF patients (42). Furthermore, roflumilast 
treatment of lung fibroblasts has been found to decrease CCL5/RANTES and CXCL10/IP-10 
expression(43).  Finally, forskolin-mediated induction of cAMP levels was shown to inhibit 
CCL11/eotaxin production by bronchial epithelial cells (44).  In addition to its effect on plasma 
chemokine levels, we also found that PDE4 inhibition decreased the day 21 lung expression 
levels of TNFα.  Prior studies using adenoviral-mediated gene transfer suggest a direct role for 
this cytokine in fibrogenesis (45).  On the other hand, the expression of TNFα in the alveolar 
compartment in the setting of a second hit (e.g. bleomycin) actually limited the fibrotic response 
(46).  Furthermore, the intratracheal instillation of recombinant TNFα to bleomycin-injured mice 
with established fibrosis resulted in improvement in the severity of scarring (47). These 
disparate results suggest that the effect of TNFα on fibrosis is complex and may depend on the 
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timing and location of its expression.  Ultimately, future studies are necessary to establish a 
causal link between the PDE4 inhibition-mediated reduction in cytokine/chemokine levels and 
the amelioration of fibrosis.  However, the efficacy of both Compound 1 and roflumilast when 
initiated at a time point when the monocyte/macrophages have already maximally accrued 
suggests that the anti-fibrotic effect of PDE4 inhibition occurs predominantly through 
mechanisms other than blocking inflammation. 
In conclusion, we have found that PDE4 inhibition significantly reduces lung fibrosis 
induced by targeted type II AEC injury.  The antifibrotic activity of this class of drugs appears to 
be mediated through an array of cellular effects that promote the integrity of the alveolar 
epithelium and inhibit pro-fibrotic gene expression by lung fibroblasts.  The equal potency of 
therapeutic PDE4 inhibition compared to the FDA approved drugs in a model of lung fibrosis 
that shares pathogenic features with the human disease serves as strong motivation to 
investigate the efficacy of roflumilast or Compound 1 in patients with IPF.  The absence of CYP 
inhibitory activity of Compound 1 suggests that it will have fewer drug-drug interactions than 
roflumilast and may be a more attractive candidate for early phase clinical trials. 
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Figure Legends: 
 
Figure 1:  The pharmacokinetics of Compound 1 administration.  10.0 mg/kg of Compound 1 
was administered by oral gavage at time 0.  Plasma and BALF were collected simultaneously 
from separate cohorts of mice at 0.5, 1, 2, 4, 8 and 24 hours after the dosing.  The plasma 
concentration of drug over time (1A) and the BALF cAMP levels over time (1B) are reported.  A 
linear relationship between plasma drug level and BALF cAMP concentration was observed 
(1C).  Data is reported as mean ± SD (n= 4/group).  
 
Figure 2:   Prophylactic administration of roflumilast and piclamilast to targeted type II AEC-
injured mice reduces weight loss and ameliorates pulmonary fibrosis.  DTR-expressing mice 
(DTR+) were administered daily I.P. PBS or DT from day 0 through Day 14.  Subsets of the 
DTR+:DT-injured animals were treated by oral gavage once daily beginning on day 0 with 
vehicle, roflumilast (1.0 mg/kg or 5.0 mg/kg), or Piclamilast at 30 mg/kg.  Mice were weighed 
daily (A) and on day 21, lungs were harvested and analyzed for total collagen content using an 
assay for hydroxyproline (B).   Data is reported as mean ± SEM (n = 10 per group).  Weight 
curves are analyzed with a two-way ANOVA + Tukey multiple comparison tests (# p ≤ 0.05 for 
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DTR+:DT Piclamilast-treatment versus DTR+:DT vehicle treatment.  ## p ≤ 0.05 DTR+:DT 
piclamilast and roflumilast (1.0 mg/kg or 5.0 mg/kg) treatment versus DTR+:DT vehicle 
treatment), and hydroxyproline is analyzed with a one-way ANOVA + Tukey multiple 
comparison tests.  
 
Figure 3:   Prophylactic administration of Compound 1 to targeted type II AEC-injured mice 
reduces weight loss and ameliorates pulmonary fibrosis.  DTR-expressing mice (DTR+) were 
administered daily I.P. PBS or DT from day 0 through Day 14.  Subsets of the DTR+:DT treated 
animals were treated by oral gavage once daily beginning on day 0 with vehicle, Compound 1  
(1.0 mg/kg, 5.0 mg/kg, or 10.0 mg/kg) or Piclamilast at 30 mg/kg.  Mice were weighed daily (A) 
and on day 21, lungs were harvested and analyzed for total collagen content using an assay for 
hydroxyproline (B).   Data is reported as mean ± SEM (n = 8 per group).  Weight curves are 
analyzed with a two-way ANOVA + Tukey multiple comparison tests (# p ≤ 0.05 for DTR+:DT 
piclamilast and Compound 1-treatments (all doses) versus DTR+:DT vehicle treatment), and 
hydroxyproline is analyzed with a one-way ANOVA + Tukey multiple comparison tests.  
  
 
Figure 4:   Therapeutic administration of Compound 1 and roflumilast to targeted type II AEC-
injured mice reduces weight loss and ameliorates pulmonary fibrosis.  DTR-expressing mice 
(DTR+) were administered daily I.P. PBS or DT from day 0 through Day 14.  Subsets of the 
DTR+:DT treated animals were treated by oral gavage once daily beginning on day 11 with 
vehicle, roflumilast (5.0 mg/kg), or Compound 1  (1.0 mg/kg or 5.0 mg/kg).  Mice were weighed 
daily (A) and on day 21, lungs were harvested and analyzed for total collagen content using an 
assay for hydroxyproline (B) and by histopathology (C) with representative sections stained with 
picrosirius red (400x magnification).   Data is reported as mean ± SEM (n = 10-12 per group).  
Weight curves are analyzed with a two-way ANOVA + Tukey multiple comparison tests (# p ≤ 
0.05 for DTR+:DT roflumilast and Compound 1 (5.0 mg/kg)-treatments versus DTR+:DT vehicle 
treatment), and hydroxyproline is analyzed with a one-way ANOVA + Tukey multiple 
comparison tests.  
  
 
Figure 5:   Compound 1 treatment of A549 human lung epithelial cell cultures increases 
intracellular and extracellular cAMP concentrations.  A549 human lung epithelial cells were 
seeded in a 24 well plate for 24 hours.  The cultures were treated with increasing concentrations 
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of Compound 1 (1×10-10 M - 1×10-5
 
) for 30 minutes and stimulated with 10 μM forskolin and 10 
μM prostaglandin E2 for 30 minutes. cAMP concentrations were measured in cell lysates (A) 
and culture supernatants (B).  The correlation between intracellular cAMP and cAMP in the 
culture supernatants is shown in (C).  Data is reported as mean + SD (n = 3 per group).  
Figure 6:   Prophylactic treatment of targeted type II AEC injured mice with Compound 1 
reduces plasma SP-D levels.  DTR-expressing mice (DTR+) were administered daily I.P. PBS 
or DT from day 0 through Day 14.  Subsets of the DTR+:DT treated animals were treated by 
oral gavage once daily beginning on day 0 with vehicle, Compound 1  (1.0 mg/kg, 5.0 mg/kg, or 
10.0 mg/kg) or Piclamilast at 30 mg/kg.  Plasma was collected on day 21 and analyzed for SP-D 
concentration (A).  The plasma SP-D concentration was then correlated with lung collagen 
content (B).   Data is reported as mean +SEM with individual data points shown (n = 8 per 
group).  #; p ≤ 0.05 vs. Vehicle group by two-tailed Williams' test. $: p ≤ 0.05 vs. Vehicle group 
by Student's t-test. 
 
 
Figure 7:   Therapeutic treatment of targeted type II AEC injured mice with Compound 1 
reduces plasma cytokine levels.  DTR-expressing mice (DTR+) were administered daily I.P. 
PBS or DT from day 0 through Day 14.  Subsets of the DTR+:DT treated animals were treated 
by oral gavage once daily beginning on day 0 with vehicle or Compound 1  at 5.0 mg/kg.  
Plasma was collected on day 21 and analyzed for CCL11/eotaxin, CXCL10/IP-10, CXCL5/LIX, 
and CCL5/Rantes.  Data is reported as mean ± SD with individual data points shown (n = 13 for 
control, 22 for Compound 1 per group).  #: p ≤ 0.05 vs. Control group by Student's t-test. 
 
 
Figure 8:   Compound 1 treatment of human lung fibroblasts cell cultures increases intracellular 
cAMP and decreases TGF-β-mediated induction of fibrotic gene expression.  WI-38 human lung 
fibroblasts were seeded on 24-well plates and treated with increasing concentrations of 
Compound 1 (1×10-10 M - 1×10-5 M). After 30 min, cells were stimulated by 1 μM forskolin for 30 
minutes and cell lysates were analyzed for cAMP concentration (A).  To analyze fibroblast gene 
expression, WI-38 human lung fibroblasts were cultured in media containing 0.5% FBS for 24 
hours and treated with increasing concentrations of Compound 1 (1×10-10 M - 1×10-5 M) for 1 
hour followed by TGF-β (3 ng/mL) and forskolin (1 μM) for 24 hours. Total RNA was extracted 
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from cell lysates, cDNA was amplified, and target gene mRNA was measured.  The target gene 
expression levels of Col1a1 (Type-1 collagen), Fn (Fibronectin), CTGF (connective tissue 
growth factor) and PAI-1 (plasminogen activator inhibitor-1) was normalized to Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH).  Data is reported as mean ± SD with individual data 
points shown (n = 3 per group).  #; p ≤ 0.05 vs. forskolin group by two-tailed Williams' test. 
 
Figure 9:  Therapeutic administration of Compound 1 to targeted type II AEC injured mice 
reduces the expression of TNFα within the lung.  DTR-expressing mice (DTR+) were 
administered daily I.P. PBS or DT from day 0 through Day 14.  Subsets of the DTR+:DT treated 
animals were treated by oral gavage once daily beginning on day 11 with vehicle or Compound 
1  at 5.0 mg/kg.  On day 21, the left lung was harvested and homogenized, and total RNA was 
extracted.  First-strand cDNA was synthesized and mRNA levels for Col1a1, Fibronectin, CTGF 
TNFα and PAI-1 (plasminogen activator inhibitor-1) were assessed using SYBR Green-based 
detection. The expression levels were normalized to GAPDH using the following formula: 
%GAPDH expression = 100/ 2-ΔΔCT.  Data is presented as an average ± SEM (n = 9 per 
DTR+:DT vehicle and drug treated groups).   
 
Figure 10: Roflumilast is equivalent to pirfenidone and nintedanib in ameliorating fibrosis 
following targeted type II AEC injury.  DTR-expressing mice (DTR+) were administered daily I.P. 
PBS or DT from day 0 through Day 14.  Subsets of the DTR+:DT treated animals were treated 
by oral gavage beginning on day 11 with vehicle, roflumilast at 5.0 mg/kg once daily, pirfenidone 
at 100.0 mg/kg three times daily, or nintedanib 100.0 mg/kg two times daily.  Mice were weighed 
daily (A) and on day 21, lungs were harvested and analyzed for total collagen content using an 
assay for hydroxyproline (B).   Data is reported as mean ± SEM (n = 6-10 per group).  Weight 
curves are analyzed with a two-way ANOVA + Tukey multiple comparison tests (# p ≤ 0.05 for 
DTR+:DT roflumilast and pirfenidone-treatment versus DTR+:DT nintedanib treatment, and 
hydroxyproline is analyzed with a one-way ANOVA + Tukey multiple comparison tests.  
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